Suppliers and packagers for spironolactone

spironolactone

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	SPIRONOLACTONE	spironolactone	SUSPENSION;ORAL	215572	ANDA	Amneal Pharmaceuticals NY LLC	69238-2027-2	473 mL in 1 BOTTLE (69238-2027-2)	2023-09-08
Amneal	SPIRONOLACTONE	spironolactone	SUSPENSION;ORAL	215572	ANDA	Amneal Pharmaceuticals NY LLC	69238-2027-8	118 mL in 1 BOTTLE (69238-2027-8)	2023-09-08
Hetero Labs Ltd Iii	SPIRONOLACTONE	spironolactone	SUSPENSION;ORAL	218085	ANDA	Camber Pharmaceuticals, Inc.	31722-691-11	118 mL in 1 BOTTLE (31722-691-11)	2025-02-21
Hetero Labs Ltd Iii	SPIRONOLACTONE	spironolactone	SUSPENSION;ORAL	218085	ANDA	Camber Pharmaceuticals, Inc.	31722-691-47	473 mL in 1 BOTTLE (31722-691-47)	2025-02-21

Spironolactone API Suppliers: Global Landscape and Market Dynamics

Last updated: February 19, 2026

Spironolactone is a potassium-sparing diuretic used to treat heart failure, high blood pressure, and hypokalemia. It is also used to treat conditions caused by excess aldosterone, such as hyperaldosteronism and hirsutism in women. The global spironolactone active pharmaceutical ingredient (API) market is characterized by established manufacturers with significant production capacity and a diverse geographical distribution. China and India are primary suppliers, alongside European and North American entities. Market dynamics are influenced by regulatory compliance, cost-effectiveness, and supply chain reliability.

Who Are the Leading Spironolactone API Manufacturers?

The manufacturing of spironolactone API is concentrated among a select group of companies with established global reach and adherence to stringent quality standards. These manufacturers typically possess large-scale production facilities and robust quality management systems, including Good Manufacturing Practices (GMP) certifications.

Manufacturer Name	Country of Origin	Primary Market Reach	Key Certifications
Teva Pharmaceutical Industries Ltd.	Israel	Global	US FDA, EMA, WHO GMP
Mylan N.V. (now Viatris)	United States	Global	US FDA, EMA, PMDA
Gland Pharma Limited	India	Global	US FDA, EMA, ANVISA
Dr. Reddy's Laboratories	India	Global	US FDA, EMA, KFDA
Sun Pharmaceutical Industries Ltd.	India	Global	US FDA, EMA, TGA
Aurobindo Pharma Ltd.	India	Global	US FDA, EMA, Health Canada
IOL Chemicals and Pharmaceuticals Ltd.	India	Global	US FDA, EDQM (CEP), WHO GMP
Sanofi S.A.	France	Global	US FDA, EMA, MFDS
Divi's Laboratories Ltd.	India	Global	US FDA, EDQM (CEP), PMDA
BASF SE	Germany	Global	US FDA, EMA

Source: Company reports, industry databases, regulatory filings.

What Are the Dominant Geographic Regions for Spironolactone API Production?

Asia, particularly India and China, represents the largest hub for spironolactone API manufacturing due to cost advantages and a well-developed chemical and pharmaceutical industry infrastructure. European and North American manufacturers also contribute, often focusing on specialized or higher-purity grades and serving regulated markets.

• Asia:
  • India: A major global supplier, with numerous manufacturers producing API for both domestic consumption and export. Companies here benefit from skilled labor and established expertise in generic API production.
  • China: Another significant producer, known for its large-scale manufacturing capabilities and competitive pricing. Chinese suppliers play a crucial role in the global supply chain for many APIs, including spironolactone.
• Europe:
  • Manufacturers in countries like Germany and France contribute to the global supply, often adhering to stringent European Medicines Agency (EMA) regulations and serving the European market and other high-regulation countries.
• North America:
  • While production within North America is less dominant in volume compared to Asia, some manufacturers exist and are critical for regional supply chain security and compliance with U.S. Food and Drug Administration (FDA) standards.

What Regulatory Standards Must Spironolactone API Suppliers Meet?

Suppliers of spironolactone API must adhere to rigorous quality and safety standards set by regulatory bodies in their target markets. Compliance is essential for market access and patient safety.

• Good Manufacturing Practices (GMP): All API manufacturers must comply with GMP guidelines specific to their manufacturing location and target markets (e.g., US FDA cGMP, EU GMP). This ensures consistent production and quality control.
• Drug Master Files (DMFs): Manufacturers typically file DMFs with regulatory agencies like the FDA and EMA. These confidential documents contain detailed information about the manufacturing process, facilities, and quality controls of the API.
• Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP): For the European market, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) demonstrates that the API complies with the European Pharmacopoeia monograph.
• Pharmacopoeial Standards: The API must meet the specifications outlined in relevant pharmacopoeias, such as the United States Pharmacopeia (USP) or the European Pharmacopoeia (Ph. Eur.).
• Impurity Profiling: Manufacturers are required to identify and control impurities within specified limits to ensure API safety and efficacy. This includes genotoxic impurities and residual solvents.
• ICH Guidelines: Compliance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly those related to quality (e.g., ICH Q7 for API GMP), is standard practice.

How Does the Supply Chain for Spironolactone API Function?

The spironolactone API supply chain involves raw material sourcing, chemical synthesis, purification, quality testing, packaging, and distribution to pharmaceutical formulation companies. Reliability and traceability are critical.

1. Raw Material Sourcing: Procurement of starting materials and key intermediates. Suppliers must ensure the quality and consistency of these inputs.
2. Synthesis and Purification: Multi-step chemical processes are employed to synthesize the spironolactone molecule. Rigorous purification steps remove unwanted byproducts.
3. Quality Control and Assurance: Extensive testing is conducted at various stages of production and on the final API batch to confirm identity, purity, potency, and compliance with pharmacopoeial standards.
4. Packaging and Storage: The API is packaged in appropriate containers to maintain its stability and prevent contamination during transport and storage. Specific storage conditions are often required.
5. Distribution: The API is shipped to pharmaceutical companies that will formulate it into finished dosage forms (tablets, capsules). Logistics and timely delivery are key.

Key Considerations for Supply Chain Reliability:

• Dual Sourcing: Pharmaceutical companies often seek multiple suppliers to mitigate the risk of supply disruption.
• Geopolitical Stability: Manufacturers' locations in politically stable regions are preferred to avoid supply interruptions.
• Regulatory Approvals: Ensuring all manufacturing sites and processes are approved by relevant health authorities.
• Audits: Regular audits of API suppliers by formulators to verify compliance with quality standards.

What are the Key Factors Influencing Spironolactone API Pricing?

Spironolactone API pricing is determined by a confluence of manufacturing costs, market demand, regulatory compliance expenses, and competitive pressures.

• Cost of Raw Materials: Fluctuations in the prices of chemical precursors directly impact API production costs.
• Manufacturing Scale and Efficiency: Larger-scale production generally leads to lower per-unit costs. Manufacturers with highly optimized processes have a cost advantage.
• Regulatory Compliance Costs: Investments in GMP infrastructure, quality control, and documentation for regulatory submissions are significant.
• Geographic Location of Manufacturing: Labor costs, energy prices, and environmental regulations vary by region, influencing overall production expenses. Manufacturers in India and China often have lower operational costs.
• Market Demand and Competition: High demand and limited supply can drive prices up, while intense competition among multiple suppliers can exert downward pressure on pricing.
• Purity and Grade: Higher purity grades or API manufactured under specific stringent conditions may command premium pricing.
• Supply Chain Disruptions: Events like natural disasters, geopolitical issues, or raw material shortages can lead to temporary price increases due to supply constraints.

How Do Different Suppliers Differentiate Themselves?

Spironolactone API suppliers differentiate themselves through a combination of quality assurance, regulatory expertise, cost competitiveness, and supply chain management.

• Quality and Regulatory Compliance: Suppliers with a strong track record of successful regulatory inspections (FDA, EMA) and a robust GMP system are highly valued. Offering detailed DMFs and CEPs is a competitive advantage.
• Cost-Effectiveness: Manufacturers in regions with lower operating costs, such as India and China, can offer more competitive pricing, particularly for high-volume generic drug production.
• Supply Chain Security and Reliability: Suppliers who can demonstrate a consistent and robust supply chain, including dual sourcing of key intermediates and contingency planning, are preferred.
• Technical Support and Documentation: Providing comprehensive technical support, including detailed analytical data and method validation, aids formulators.
• Product Consistency: Maintaining batch-to-batch consistency in API quality is paramount for pharmaceutical manufacturers.
• Sustainability Practices: Increasingly, environmental, social, and governance (ESG) factors are becoming a consideration for some purchasers.

What are the Future Trends in Spironolactone API Supply?

The spironolactone API market is expected to evolve with an emphasis on supply chain resilience, advanced quality control, and potentially, shifts in manufacturing geography driven by regulatory and economic factors.

• Increased Focus on Supply Chain Resilience: Pharmaceutical companies are prioritizing suppliers with robust risk management strategies and diversified sourcing to mitigate disruptions.
• Technological Advancements in Manufacturing: Adoption of advanced manufacturing technologies to improve efficiency, reduce waste, and enhance API quality. This includes process analytical technology (PAT).
• Stringent Impurity Control: Growing regulatory scrutiny on impurities, including potential genotoxic impurities, will require suppliers to invest in advanced analytical capabilities and process controls.
• Consolidation and Strategic Partnerships: The market may see further consolidation as larger players acquire smaller ones or form strategic alliances to enhance market share and operational efficiency.
• Geographic Diversification: While Asia remains dominant, some pharmaceutical companies may seek to diversify sourcing to include more suppliers in regulated markets to enhance supply chain security and reduce reliance on single regions.
• Digitalization of Quality Management: Implementation of digital tools for quality management systems, batch tracking, and supply chain visibility.

Key Takeaways

• The spironolactone API market is dominated by manufacturers in India and China, leveraging cost advantages and established infrastructure.
• Leading global suppliers include Teva, Viatris, Gland Pharma, and Dr. Reddy's Laboratories, among others.
• Adherence to stringent regulatory standards, including GMP, DMF filing, and pharmacopoeial compliance, is critical for market access.
• Pricing is influenced by raw material costs, manufacturing efficiency, regulatory expenses, and market competition.
• Differentiation among suppliers is achieved through quality, regulatory track record, cost, and supply chain reliability.
• Future trends point towards enhanced supply chain resilience, advanced quality control, and increasing regulatory oversight on impurities.

FAQs

1. What is the typical lead time for ordering spironolactone API from a major supplier? Lead times can vary significantly depending on the supplier's current inventory, production schedules, and the specific order volume, but generally range from 4 to 12 weeks from order confirmation to delivery.
2. Are there any specific environmental regulations that spironolactone API manufacturers must comply with? Yes, manufacturers must comply with local and international environmental regulations pertaining to chemical synthesis, waste disposal, and emissions, which can vary significantly by country and region.
3. How does the purity of spironolactone API affect its price? Higher purity grades, meeting stricter pharmacopoeial requirements or with extremely low levels of specific impurities, typically command a higher price due to the more rigorous purification processes and analytical testing involved.
4. What are the primary risks associated with the spironolactone API supply chain? Primary risks include raw material price volatility, geopolitical instability in sourcing regions, regulatory non-compliance by suppliers, quality control failures, and transportation disruptions.
5. Can a pharmaceutical company use API from multiple suppliers for the same drug product? Yes, pharmaceutical companies often qualify multiple API suppliers as part of their supply chain risk mitigation strategy. However, each supplier's API must meet the same approved specifications and undergo rigorous validation for use in the specific drug product.

Citations

[1] Teva Pharmaceutical Industries Ltd. (n.d.). Investor Relations. Retrieved from [company website] [2] Viatris Inc. (n.d.). Our Business. Retrieved from [company website] [3] Gland Pharma Limited. (n.d.). About Us. Retrieved from [company website] [4] Dr. Reddy's Laboratories. (n.d.). Our Products. Retrieved from [company website] [5] Sun Pharmaceutical Industries Ltd. (n.d.). API Division. Retrieved from [company website] [6] Aurobindo Pharma Ltd. (n.d.). API Manufacturing. Retrieved from [company website] [7] IOL Chemicals and Pharmaceuticals Ltd. (n.d.). Products. Retrieved from [company website] [8] Sanofi S.A. (n.d.). Our Business Units. Retrieved from [company website] [9] Divi's Laboratories Ltd. (n.d.). Products & Services. Retrieved from [company website] [10] BASF SE. (n.d.). Pharmaceuticals. Retrieved from [company website] [11] European Medicines Agency. (n.d.). Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EMA website] [12] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website] [13] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website] [14] United States Pharmacopeia. (n.d.). USP Standards. Retrieved from [USP website] [15] European Directorate for the Quality of Medicines & HealthCare. (n.d.). The European Pharmacopoeia. Retrieved from [EDQM website]